← board
BSEM
distress 0/10 · well-funded / low risk$3.98+1%today-68% from 52w high
Revenue
$10M
Liquidity
$27M
Runway
—
Shares 1y
—
Price & events
-24.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.3%
1D
+6.2%
1W
+7.6%
1M
-10.6%
3M
-44.3%
6M
-64.0%
1Y
-52.7%
2Y
+218.4%
5Y
+148.7%
All
Overview
- Volume
- 130
- 52 Week Range
- $3.22 – $12.52
- RVOL
- 0.00x
- Beta
- 0.21
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-13BioStem Technologies files Form 10 registration statement with SEC - Medical Buyer
- 2026-07-10BioStem Technologies Publicly Files Form 10 Registration Statement with the Securities and Exchange Commission - GlobeNewswire
- 2026-07-10BioStem Technologies (BSEM) files Form 10; acquires BioTissue assets, targets Catalyze launch in Q4 2026 - Stock Titan
- 2026-07-10BioStem Technologies files Form 10 to pursue Nasdaq uplisting - scanx.trade
- 2026-07-08BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies - ACCESS Newswire
- 2026-07-08BioStem wins four U.S. design patents for placental allografts - Stock Titan
- 2026-06-09BioStem Technologies Announces Appointment of Three New Members to its Board of Directors - GlobeNewswire
- 2026-06-09Hospital chief, biotech exec and investor join BioStem board - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.